Alovudine is a reverse transcriptase inhibitor potentially for the treatment of HIV infection. A 4-week randomized, double-blind, placebo-controlled dose-ranging study concluded that alovudine 2 mg/day provided a modest but significant viral load reduction in patients harbouring viruses.
Properties:
Appearance & Physical State: Colourless solid
Density: 1.44 g/cm3
Melting Point: 176-178ºC(lit.)
Refractive Index: 1.565
Reverse Transcriptase Inhibitors Related Prodcuts:
Didanosine; Dapivirine; Tenofovir; Emtricitabine; Entecavir; Entecavir hydrate; Adefovir; Adefovir dipivoxil; Nevirapine; Lamivudine; Stavudine; Telbivudine; Etravirine; Zidovudine; Zalcitabine